ARTH:OTC-Arch Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.17

Change

0.00 (-1.13)%

Market Cap

USD 0.03B

Volume

0.06M

Average Target Price

USD 1.38 (+728.31%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.66 (-0.99%)

USD152.23B 27.18 2.70
CSLLY CSL Limited

-1.97 (-1.72%)

USD104.10B 46.54 27.25
CMXHF CSL Limited

N/A

USD104.10B 50.12 27.25
GNMSF Genmab A/S

+11.90 (+3.28%)

USD23.59B 101.26 2.65
UCBJY UCB SA

-1.04 (-1.90%)

USD20.60B 23.17 17.71
UCBJF UCB SA

N/A

USD20.60B 23.96 17.71
SBMFF Sino Biopharmaceutical Limited

N/A

USD20.37B 31.52 3.18
SBHMY Sino Biopharmaceutical Limited

N/A

USD18.59B 52.10 3.18
PPTDF PeptiDream Inc

N/A

USD6.03B 260.99 1.61
ABCZY Abcam plc

+0.55 (+2.98%)

USD4.35B 236.08 106.86

ETFs Containing ARTH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.49% 22% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.49% 22% F 21% F
Trailing 12 Months  
Capital Gain -42.36% 19% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -42.36% 19% F 17% F
Trailing 5 Years  
Capital Gain -7.78% 64% D 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.78% 63% D 46% F
Average Annual (5 Year Horizon)  
Capital Gain 7.42% N/A N/A 58% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.42% N/A N/A 54% F
Risk Return Profile  
Volatility (Standard Deviation) 80.47% N/A N/A 30% F
Risk Adjusted Return 9.22% N/A N/A 45% F
Market Capitalization 0.03B 63% D 48% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -6.15 63% D 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -2,306.39% 1% F 1% F
Return on Assets -99.54% 34% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.19 72% C- 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.